Journal of Hematological Malignancies（ISSN 1925-4024，EISSN 1925-4032）is an open access international scientific journal providing a forum for peer-reviewed articles, reviews or commentary related to all aspects of the prevention, diagnosis and management of malignancies of the blood system, as well as related molecular and cell biology, genetics, pathophysiology, epidemiology, and randomized controlled trials and evidence-based meta-analysis or pooled analysis related to specific trials.
JHM is included in:
- Gale's Academic Databases
- Google Scholar
- PKP Open Archives Harvester
Original Research, Case Report, Conference Report, Reviews.
2013 Q1: Articles Received: 8; Accepted: 1; Rejected: 7
What is e-Version FirstTM
e-Version First is a feature offered through our journal platform. It allows PDF version of manuscripts that have been peer reviewed and accepted, to be hosted online prior to their inclusion in a final printed journal. Readers can freely access or cite the article. We aim to publish accepted manuscripts in e-Version First in two week's time after the final draft completed.
Paper Selection and Publication Process
a). Upon receipt of paper submission, the Editor sends an E-mail of confirmation to the corresponding author within 1-3 working days. If you fail to receive this confirmation, your submission/e-mail may be missed. Please contact the Editor in time for that.
b). Peer review. We use double-blind system for peer-review; both reviewers and authors' identities remain anonymous. The paper will be peer-reviewed by three experts; two reviewers from outside and one editor from the journal typically involve in reviewing a submission. The review process may take 2-3 weeks.
c). Notification of the result of review by E-mail.
d). The authors revise paper and pay publication fee (200.00 USD).
e). After publication, the corresponding author will receive two copies of printed journals, free of charge.
f). E-journal in PDF is available on the journal’s webpage, free of charge for download.
The publisher and journal have a policy of “Zero Tolerance on the Plagiarism”. We check the plagiarism issue through two methods: reviewer check and plagiarism prevention tool (ithenticate.com).
All submissions will be checked by iThenticate before being sent to reviewers.
Call for Papers: 2012 Special Issue on Intercellular communication in leukemia development and function
Special issue entitled: Intercellular communication in leukemia development and function
May 2012 Call for papers
November 2012 Deadline submission
February 2013 Finished 1st review
May 2013 Publication
Brynjar Foss, Department of Health Studies, University of Stavanger, N-4036 Stavanger, Norway
Call for Papers: 2012 Special Issue on Infections in patients with hematological malignancies
Special issue entitled: Infections in patients with hematological malignancies
Samah Loutfy, Associate professor, National Cancer Institute, Cairo University, Egypt
Special Issue Guideline
|Special Issues are an important component of The Journal of Hematological Malignancies (JHM)edited by a Guest Editor.|
New Issue Published
|Journal of Hematological Malignancies has just published its latest issue.|
Free of Charge for the first\ second issue
|The very first/second issue of the Journal of Biomedical Graphics and Computing is in the process of calling for papers.|
Call for papers of JHM
Now we are in the process of calling for papers for the very first/second issue of the Journal of Hematological Malignancies, and we will publish your work online if your paper is accepted. Please find the journal’s profile at: www.sciedu.ca/jhm and submit your manuscripts online. If you have any questions, please contact with the editorial assistant at: firstname.lastname@example.org
Journal of Hematological Malignancies(JHM)formed Editorial Review Board
|JHM'S Editorial Review Board has been established, consisting of more than 80 surgeons, radiologists, researchers and experts in blood-related conditions, as well as the treatment of hematological malignancies area.
Vol 3, No 2 (2013): Journal of Hematological Malignancies, Vol. 3, No. 2, 2013
Table of Contents
|Curcumin enhances the cytotoxic and chemo-sensitising effects of lenalidomide in human multiple myeloma cells|
|Rose Wong, Terry Golombick, Terrence H. Diamond, Arumugam Manoharan, Rajeev Ramakrishna||p1|
This work is licensed under a Creative Commons Attribution 3.0 License.
Copyright © Sciedu Press
To make sure that you can receive messages from us, please add the 'Sciedu.ca' domain to your e-mail 'safe list'. If you do not receive e-mail in your 'inbox', check your 'bulk mail' or 'junk mail' folders